Suggestions
Eric S. Alonzo
Cell & Gene Therapy Leader | CMC Management | Biomarker Discovery | Solutionist
Eric S. Alonzo is a professional in the biomedical and pharmaceutical industry with a focus on analytical development and early oncology programs.13 He currently holds the position of Director of Analytical Development at 2seventy bio, where he serves as the CMC (Chemistry, Manufacturing, and Controls) Lead for the bbT369 Program.12
Educational Background
Eric S. Alonzo received his PhD from the Gerstner Sloan-Kettering Graduate School of Biomedical Sciences at Memorial Sloan-Kettering Cancer Center.1 This prestigious educational background has likely contributed to his expertise in biomedical sciences and oncology research.
Professional Experience
Prior to his current role at 2seventy bio, Eric S. Alonzo worked at bluebird bio, where he held the following positions:
- Director of Analytical Development
- CMC Lead for Early Oncology Programs3
These roles demonstrate his progression in the field of analytical development and his specialization in oncology-related projects.
Current Role
At 2seventy bio, Eric S. Alonzo is responsible for:
- Leading the analytical development efforts for the company's programs
- Overseeing the CMC aspects of the bbT369 Program, which is likely an oncology-related initiative12
His position suggests that he plays a crucial role in ensuring the quality, safety, and efficacy of the company's biopharmaceutical products, particularly in the context of cancer treatment development.
Eric S. Alonzo's LinkedIn profile can be found under the username "ericsalonzo," where more details about his professional experience and accomplishments may be available.
